🧬 From lab to clinic: bringing genetic screening to those who need it most
We’re grateful to be featured in Zaobao, Singapore’s leading Chinese-language media outlet, where the story behind NalaGenetics — and the scientists who laid its foundation — is highlighted.
It all began with a breakthrough by researchers at A*STAR’s Genome Institute of Singapore, who discovered a genetic marker linked to severe allergic reactions (Dapsone Hypersensitivity Syndrome) in some leprosy patients. When there was no movement to bring this test to market — especially in the low-income regions that needed it most — the team rolled up their sleeves and decided to act.
That decision eventually led to NalaGenetics, and a successful pilot program in Papua, Indonesia, where our test helped reduce dapsone-related fatalities from 9.9% to nearly zero. This work is now being scaled nationwide in Indonesia — and it’s only the beginning.
Today, we screen for potential adverse reactions to over 180 commonly used drugs, and continue to expand across Asia and beyond, thanks to a mission-driven team and strong scientific roots.
📰 Read the full story (in Chinese):
https://www.zaobao.com.sg/finance/singapore/story20250626-6906142
#NalaGenetics #Pharmacogenomics #PrecisionMedicine #GeneticTesting #HealthcareInnovation #LeprosyAwareness #ImpactDriven
Leave a Reply